CoLucid Pharmaceuticals To Present At The 28th Annual Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the 28 th Annual Piper Jaffray Healthcare Conference, being held on November 29-30 in New York City.
28 th Annual Piper Jaffray Healthcare Conference
Date:    Wednesday, November 30
Time:   1:00 pm Eastern Time
Location:   The Lotte New York Palace Hotel, Holmes I Room
Webcast:   http://edge.media-server.com/m/p/cfdngzft 

About CoLucid Pharmaceuticals, Inc. CoLucid is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.

CONTACTThomas MathersChief Executive OfficerCoLucid Pharmaceuticals, Inc.(857) 285-6494Hans VitzthumManaging DirectorLifeSci Advisors, LLC.(212) 915-2568

Primary Logo

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX